- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Biochemistry Research International
Volume 2012 (2012), Article ID 895343, 11 pages
Potential Role of Peptidylarginine Deiminase Enzymes and Protein Citrullination in Cancer Pathogenesis
1Baker Institute for Animal Health and Department of Biomedical Sciences, Cornell University, Hungerford Hill Road, Ithaca, NY 14853-6401, USA
2Department of Zoology and Physiology, University of Wyoming, Laramie, WY 82071, USA
3Department of Chemistry, The Scripps Research Institute, FL 33458, USA
Received 29 May 2012; Revised 31 July 2012; Accepted 9 August 2012
Academic Editor: Rolf J. Craven
Copyright © 2012 Sunish Mohanan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. R. Vossenaar, A. J. W. Zendman, W. J. Van Venrooij, and G. J. M. Pruijn, “PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease,” BioEssays, vol. 25, no. 11, pp. 1106–1118, 2003.
- R. B. Denman, “PAD: the smoking gun behind arginine methylation signaling?” BioEssays, vol. 27, no. 3, pp. 242–246, 2005.
- C. Anzilotti, F. Pratesi, C. Tommasi, and P. Migliorini, “Peptidylarginine deiminase 4 and citrullination in health and disease,” Autoimmunity Reviews, vol. 9, no. 3, pp. 158–160, 2010.
- X. Chang, R. Yamada, A. Suzuki et al., “Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis,” Rheumatology, vol. 44, no. 1, pp. 40–50, 2005.
- X. Chang and J. Han, “Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors,” Molecular Carcinogenesis, vol. 45, no. 3, pp. 183–196, 2006.
- J. E. Jones, C. P. Causey, B. Knuckley, J. L. Slack-Noyes, and P. R. Thompson, “Protein arginine deiminase 4 (PAD4): current understanding and future therapeutic potential,” Current Opinion in Drug Discovery and Development, vol. 12, no. 5, pp. 616–627, 2009.
- M. De Ceuleneer, K. Van Steendam, M. Dhaenens, and D. Deforce, “In vivo relevance of citrullinated proteins and the challenges in their detection,” Proteomics, vol. 12, pp. 752–760, 2012.
- S. Chavanas, M. C. Méchin, H. Takahara et al., “Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6,” Gene, vol. 330, no. 1-2, pp. 19–27, 2004.
- E. R. Vossenaar, S. Nijenhuis, M. M. A. Helsen et al., “Citrullination of synovial proteins in murine models of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 48, no. 9, pp. 2489–2500, 2003.
- R. E. Ellsworth, A. Vertrees, B. Love et al., “Chromosomal alterations associated with the transition from in situ to invasive breast cancer,” Annals of Surgical Oncology, vol. 15, no. 9, pp. 2519–2525, 2008.
- E. Darrah, A. Rosen, J. T. Giles, and F. Andrade, “Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 71, pp. 92–98, 2012.
- B. Knuckley, C. P. Causey, J. E. Jones et al., “Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3,” Biochemistry, vol. 49, no. 23, pp. 4852–4863, 2010.
- L. B. Pritzker, S. Joshi, G. Harauz, and M. A. Moscarello, “Deimination of myelin basic protein. 2. Effect of methylation of MBP on its deimination by peptidylarginine deiminase,” Biochemistry, vol. 39, no. 18, pp. 5382–5388, 2000.
- L. B. Pritzker, S. Joshi, J. J. Gowan, G. Harauz, and M. A. Moscarello, “Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D,” Biochemistry, vol. 39, no. 18, pp. 5374–5381, 2000.
- A. A. Musse, L. Zhen, C. A. Ackerley et al., “Peptidylarginine deiminase 2 (PAD2) overexpression in transgenic mice leads to myelin loss in the central nervous system,” Disease Models and Mechanisms, vol. 1, no. 4-5, pp. 229–240, 2008.
- E. R. Vossenaar, T. R. D. Radstake, A. Van Der Heijden et al., “Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages,” Annals of the Rheumatic Diseases, vol. 63, no. 4, pp. 373–381, 2004.
- B. D. Cherrington, E. Morency, A. M. Struble, S. A. Coonrod, and J. J. Wakshlag, “Potential role for peptidylarginine deiminase 2 (PAD2) in citrullination of canine mammary epithelial cell histones,” PLoS ONE, vol. 5, no. 7, Article ID e11768, 2010.
- B. D. Cherrington, X. Zhang, J. L. McElwee, E. Morency, L. J. Anguish, and S. A. Coonrod, “Potential role for PAD2 in gene regulation in breast cancer cells,” PloS ONE, vol. 7, Article ID e41242, 2012.
- X. Zhang, M. Bolt, M. J. Guertin et al., “Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 33, pp. 13331–13336, 2012.
- R. Nachat, M. C. Méchin, H. Takahara et al., “Peptidylarginine deiminase isoforms 1–3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin,” Journal of Investigative Dermatology, vol. 124, no. 2, pp. 384–393, 2005.
- X. Chang and K. Fang, “PADI4 and tumourigenesis,” Cancer Cell International, vol. 10, article 7, 2010.
- K. Nakashima, T. Hagiwara, and M. Yamada, “Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49562–49568, 2002.
- X. Chang, R. Yamada, T. Sawada, A. Suzuki, Y. Kochi, and K. Yamamoto, “The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis,” Rheumatology, vol. 44, no. 3, pp. 293–298, 2005.
- A. Ordóñez, I. Martínez-Martínez, F. J. Corrales et al., “Effect of citrullination on the function and conformation of antithrombin,” The FEBS Journal, vol. 276, no. 22, pp. 6763–6772, 2009.
- A. Ordóñez, J. Yélamos, S. Pedersen et al., “Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody,” Thrombosis and Haemostasis, vol. 104, no. 6, pp. 1143–1149, 2010.
- C. Tanikawa, K. Ueda, H. Nakagawa, N. Yoshida, Y. Nakamura, and K. Matsuda, “Regulation of protein citrullination through p53/PADI4 Network in DNA damage response,” Cancer Research, vol. 69, no. 22, pp. 8761–8769, 2009.
- Q. Guo and W. Fast, “Citrullination of Inhibitor of Growth 4 (ING4) by Peptidylarginine Deminase 4 (PAD4) disrupts the interaction between ING4 and p53,” Journal of Biological Chemistry, vol. 286, no. 19, pp. 17069–17078, 2011.
- H. Yao, P. Li, B. J. Venters et al., “Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis,” Journal of Biological Chemistry, vol. 283, no. 29, pp. 20060–20068, 2008.
- P. Li, H. Yao, Z. Zhang et al., “Regulation of p53 target gene expression by peptidylarginine deiminase 4,” Molecular and Cellular Biology, vol. 28, no. 15, pp. 4745–4758, 2008.
- X. Zhang, M. J. Gamble, S. Stadler et al., “Genome-Wide analysis reveals PADI4 cooperates with Elk-1 to activate C-Fos expression in breast cancer cells,” PLoS Genetics, vol. 7, no. 6, Article ID e1002112, 2011.
- Y. Wang, M. Li, S. Stadler et al., “Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation,” Journal of Cell Biology, vol. 184, no. 2, pp. 205–213, 2009.
- C. Tanikawa, M. Espinosa, A. Suzuki et al., “Regulation of histone modification and chromatin structure by the p53-PADI4 pathway,” Nature Communications, vol. 3, article 676, 2012.
- H. L. Rust and P. R. Thompson, “Kinase consensus sequences: a breeding ground for crosstalk,” ACS Chemical Biology, vol. 6, pp. 881–892, 2011.
- P. Li, D. Wang, H. Yao et al., “Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression,” Oncogene, vol. 29, no. 21, pp. 3153–3162, 2010.
- P. Yurttas, A. M. Vitale, R. J. Fitzhenry et al., “Role for PADI6 and the cytoplasmic lattices in ribosomal storage in oocytes and translational control in the early mouse embryo,” Development, vol. 135, no. 15, pp. 2627–2636, 2008.
- S. N. Stacey, D. F. Gudbjartsson, P. Sulem et al., “Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits,” Nature Genetics, vol. 40, no. 11, pp. 1313–1318, 2008.
- P. Yurttas, E. Morency, and S. A. Coonrod, “Use of proteomics to identify highly abundant maternal factors that drive the egg-to-embryo transition,” Reproduction, vol. 139, no. 5, pp. 809–823, 2010.
- L. Li, P. Zheng, and J. Dean, “Maternal control of early mouse development,” Development, vol. 137, no. 6, pp. 859–870, 2010.
- T. Senshu, K. Akiyama, S. Nagata, K. Watanabe, and K. Hikichi, “Peptidylarginine deiminase in rat pituitary: sex difference, estrous cycle-related changes, and estrogen dependence,” Endocrinology, vol. 124, no. 6, pp. 2666–2670, 1989.
- H. Takahara, M. Tsuchida, M. Kusubata, K. Akutsu, and S. K. Tagami Sugawara, “Peptidylarginine deiminase of the mouse. Distribution, properties, and immunocytochemical localization,” Journal of Biological Chemistry, vol. 264, no. 22, pp. 13361–13368, 1989.
- K. Watanabe, M. Nomoto, S. Nagata et al., “The rat peptidylarginine deiminase-encoding gene: structural analysis and the 5'-flanking sequence,” Gene, vol. 114, no. 2, pp. 261–265, 1992.
- S. Nagata, T. Uehara, K. Inoue, and T. Senshu, “Increased peptidylarginine deiminase expression during induction of prolactin biosynthesis in a growth-hormone-producing rat pituitary cell line, MtT/S,” Journal of Cellular Physiology, vol. 150, no. 2, pp. 426–432, 1992.
- T. Barrett, D. B. Troup, S. E. Wilhite et al., “NCBI GEO: archive for high-throughput functional genomic data,” Nucleic Acids Research, vol. 37, no. 1, pp. D885–D890, 2009.
- S. C. Hewitt, B. J. Deroo, K. Hansen et al., “Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen,” Molecular Endocrinology, vol. 17, no. 10, pp. 2070–2083, 2003.
- H. Takahara, M. Kusubata, M. Tsuchida, T. Kohsaka, S. Tagami, and K. Sugawara, “Expression of peptidylarginine deiminase in the uterine epithelial cells of mouse is dependent on estrogen,” Journal of Biological Chemistry, vol. 267, no. 1, pp. 520–525, 1992.
- S. Horibata, S. A. Coonrod, and B. D. Cherrington, “Role for peptidylarginine deiminase enzymes in disease and female reproduction,” The Journal of Reproduction and Development, vol. 58, pp. 274–282, 2012.
- S. Dong, Z. Zhang, and H. Takahara, “Estrogen-enhanced peptidylarginine deiminase type IV gene (PADI4) expression in MCF-7 cells is mediated by estrogen receptor-α-promoted transfactors activator protein-1, nuclear factor-Y, and Sp1,” Molecular Endocrinology, vol. 21, no. 7, pp. 1617–1629, 2007.
- Y. Wang, J. Wysocka, J. Sayegh et al., “Human PAD4 regulates histone arginine methylation levels via demethylimination,” Science, vol. 306, no. 5694, pp. 279–283, 2004.
- A. A. Chumanevich, C. P. Causey, B. A. Knuckley et al., “Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor,” American Journal of Physiology, vol. 300, no. 6, pp. G929–G938, 2011.
- L. R. Tait, R. J. Pauley, S. J. Santner et al., “Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts,” International Journal of Cancer, vol. 120, no. 10, pp. 2127–2134, 2007.
- F. R. Miller, S. J. Santner, L. Tait, and P. J. Dawson, “MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ,” Journal of the National Cancer Institute, vol. 92, no. 14, pp. 1185–1186, 2000.
- L. Wang, X. Chang, G. Yuan, Y. Zhao, and P. Wang, “Expression of peptidylarginine deiminase type 4 in ovarian tumors,” International Journal of Biological Sciences, vol. 6, no. 5, pp. 454–464, 2010.
- X. Chang, J. Han, L. Pang, Y. Zhao, Y. Yang, and Z. Shen, “Increased PADI4 expression in blood and tissues of patients with malignant tumors,” BMC Cancer, vol. 9, article 40, 2009.
- B. D. Cherrington, S. Mohanan, A. N. Diep et al., “Comparative analysis of peptidylarginine deiminase-2 expression in canine, feline and human mammary tumours,” Journal of Comparative Pathology, vol. 147, pp. 139–146, 2012.
- J. L. Slack, C. P. Causey, and P. R. Thompson, “Protein arginine deiminase 4: a target for an epigenetic cancer therapy,” Cellular and Molecular Life Sciences, vol. 68, no. 4, pp. 709–720, 2011.
- Y. Luo, K. Arita, M. Bhatia et al., “Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization,” Biochemistry, vol. 45, no. 39, pp. 11727–11736, 2006.
- Y. Luo, B. Knuckley, Y. H. Lee, M. R. Stallcup, and P. R. Thompson, “A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation,” Journal of the American Chemical Society, vol. 128, no. 4, pp. 1092–1093, 2006.
- B. Knuckley, Y. Luo, and P. R. Thompson, “Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors,” Bioorganic and Medicinal Chemistry, vol. 16, no. 2, pp. 739–745, 2008.
- Y. Wang, P. Li, S. Wang et al., “Anticancer PAD inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity,” The Journal of Biological Chemistry, vol. 287, pp. 25941–25953, 2012.
- C. W. Van, M. G. Alison, K. B. Nirmal et al., “N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis,” Journal of Immunology, vol. 186, no. 7, pp. 4396–4404, 2011.
- B. L. Pierce, M. L. Neuhouser, M. H. Wener et al., “Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors,” Breast Cancer Research and Treatment, vol. 114, no. 1, pp. 155–167, 2009.
- O. I. Ahmed, A. M. Adel, D. R. Diab, and N. S. Gobran, “Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients,” The Egyptian Journal of Immunology, vol. 13, no. 2, pp. 61–68, 2006.
- T. Bachelot, I. Ray-Coquard, C. Menetrier-Caux, M. Rastkha, A. Duc, and J. Y. Blay, “Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients,” British Journal of Cancer, vol. 88, no. 11, pp. 1721–1726, 2003.
- S. W. Cole, “Chronic inflammation and breast cancer recurrence,” Journal of Clinical Oncology, vol. 27, no. 21, pp. 3418–3419, 2009.
- R. Salgado, S. Junius, I. Benoy et al., “Circulating interleukin-6 predicts survival in patients with metastatic breast cancer,” International Journal of Cancer, vol. 103, no. 5, pp. 642–646, 2003.
- G. J. Zhang and I. Adachi, “Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma,” Anticancer Research, vol. 19, no. 2, pp. 1427–1432, 1999.
- L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002.
- I. J. Fidler, “The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited,” Nature Reviews Cancer, vol. 3, no. 6, pp. 453–458, 2003.
- I. Auger, C. Charpin, N. Balandraud, M. Martin, and J. Roudier, “Autoantibodies to PAD4 and BRAF in rheumatoid arthritis,” Autoimmunity Reviews, vol. 11, no. 11, pp. 801–803, 2012.
- M. Saffarzadeh, C. Juenemann, M. A. Queisser et al., “Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones,” PloS ONE, vol. 7, Article ID e32366, 2012.
- C. L. Liu, S. Tangsombatvisit, J. M. Rosenberg et al., “Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies,” Arthritis Research & Therapy, vol. 14, article R25, 2012.
- B. Amulic and G. Hayes, “Neutrophil extracellular traps,” Current Biology, vol. 21, no. 9, pp. R297–R298, 2011.
- P. Li, M. Li, M. R. Lindberg, M. J. Kennett, N. Xiong, and Y. Wang, “PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps,” Journal of Experimental Medicine, vol. 207, no. 9, pp. 1853–1862, 2010.
- L. Fan, D. He, Q. Wang et al., “Citrullinated vimentin stimulates proliferation, pro-inflammatory cytokine secretion, and PADI4 and RANKL expression of fibroblast-like synoviocytes in rheumatoid arthritis,” Scandinavian Journal of Rheumatology. In press.
- H. J. Lee, M. Joo, R. Abdolrasulnia et al., “Peptidylarginine deiminase 2 suppresses inhibitory κB kinase activity in lipopolysaccharide-stimulated RAW 264.7 macrophages,” Journal of Biological Chemistry, vol. 285, no. 51, pp. 39655–39662, 2010.
- V. Ruiz-Esquide, M. J. Gomara, V. I. Peinado et al., “Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?” Clinical Rheumatology, vol. 31, pp. 1047–1050, 2012.
- O. Kilsgard, P. Andersson, M. Malmsten et al., “Peptidylarginine deiminases present in the airways during tobacco smoking and inflammation can citrullinate the host defense peptide LL-37, resulting in altered activities,” American Journal of Respiratory Cell and Molecular Biology, vol. 46, pp. 240–248, 2012.
- D. Makrygiannakis, E. Af Klint, I. E. Lundberg et al., “Citrullination is an inflammation-dependent process,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1219–1222, 2006.
- F. Coudane, M. C. Mechin, A. Huchenq et al., “Deimination and expression of peptidylarginine deiminases during cutaneous wound healing in mice,” European Journal of Dermatology, vol. 21, no. 3, pp. 376–384, 2011.
- A. Mortier, M. Gouwy, J. Van Damme, and P. Proost, “Effect of posttranslational processing on the in vitro and in vivo activity of chemokines,” Experimental Cell Research, vol. 317, no. 5, pp. 642–654, 2011.
- P. Proost, T. Loos, A. Mortier et al., “Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation,” Journal of Experimental Medicine, vol. 205, no. 9, pp. 2085–2097, 2008.